![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CFAP69 |
Gene summary for CFAP69 |
![]() |
Gene information | Species | Human | Gene symbol | CFAP69 | Gene ID | 79846 |
Gene name | cilia and flagella associated protein 69 | |
Gene Alias | C7orf63 | |
Cytomap | 7q21.13 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A5D8W1 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
79846 | CFAP69 | PTC05 | Human | Thyroid | PTC | 2.31e-02 | 1.36e-01 | 0.2065 |
79846 | CFAP69 | PTC06 | Human | Thyroid | PTC | 3.49e-02 | 7.84e-02 | 0.2057 |
79846 | CFAP69 | PTC07 | Human | Thyroid | PTC | 1.11e-03 | 6.38e-02 | 0.2044 |
79846 | CFAP69 | ATC13 | Human | Thyroid | ATC | 2.57e-60 | 1.12e+00 | 0.34 |
79846 | CFAP69 | ATC5 | Human | Thyroid | ATC | 4.74e-72 | 1.19e+00 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00328866 | Thyroid | PTC | regulation of microtubule-based process | 105/5968 | 240/18723 | 6.91e-05 | 6.03e-04 | 105 |
GO:003288613 | Thyroid | ATC | regulation of microtubule-based process | 114/6293 | 240/18723 | 5.17e-06 | 5.59e-05 | 114 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CFAP69 | SNV | Missense_Mutation | novel | c.775C>T | p.Arg259Cys | p.R259C | A5D8W1 | protein_coding | deleterious(0.04) | benign(0.189) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CFAP69 | SNV | Missense_Mutation | novel | c.2302A>C | p.Lys768Gln | p.K768Q | A5D8W1 | protein_coding | tolerated(0.11) | possibly_damaging(0.73) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CFAP69 | SNV | Missense_Mutation | novel | c.826N>T | p.Val276Phe | p.V276F | A5D8W1 | protein_coding | deleterious(0.03) | benign(0.232) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
CFAP69 | SNV | Missense_Mutation | novel | c.1978N>A | p.Leu660Ile | p.L660I | A5D8W1 | protein_coding | deleterious(0.01) | possibly_damaging(0.857) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CFAP69 | SNV | Missense_Mutation | c.2267N>G | p.Ile756Ser | p.I756S | A5D8W1 | protein_coding | deleterious(0) | benign(0.295) | TCGA-AX-A05W-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CFAP69 | SNV | Missense_Mutation | c.2517C>A | p.Phe839Leu | p.F839L | A5D8W1 | protein_coding | tolerated(0.11) | benign(0.269) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CFAP69 | SNV | Missense_Mutation | novel | c.1033N>A | p.Val345Ile | p.V345I | A5D8W1 | protein_coding | tolerated(0.07) | probably_damaging(0.994) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
CFAP69 | SNV | Missense_Mutation | novel | c.652C>A | p.Leu218Ile | p.L218I | A5D8W1 | protein_coding | tolerated(0.13) | possibly_damaging(0.586) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
CFAP69 | SNV | Missense_Mutation | novel | c.1882C>A | p.Leu628Ile | p.L628I | A5D8W1 | protein_coding | tolerated(0.37) | benign(0.301) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
CFAP69 | SNV | Missense_Mutation | novel | c.2164A>C | p.Ile722Leu | p.I722L | A5D8W1 | protein_coding | tolerated(0.21) | benign(0.085) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |